bluuebunny/crossref_metadata_2025_split huggingface dataset:
Monocytic fasciitis: A newly recognized clinical feature of tumor necrosis factor receptor dysfunction
Authors: Hull Keith M. , Wong Kondi , Wood Geryl M. , Chu Wei‐Sing , Kastner Daniel L. 
Published: October 2002

AbstractTumor necrosis factor receptor–associated periodic syndrome (TRAPS) is a dominantly inherited autoinflammatory syndrome that results from mutations in TNFRSF1A, the gene that encodes the 55‐kd tumor necrosis factor receptor. Clinically, patients present with recurrent episodes of fever in conjunction with localized inflammation at various sites. Myalgia is one of the most characteristic features of this syndrome and is frequently associated with an overlying erythematous, macular rash that, together with the myalgia, displays centrifugal migration. This has previously been believed to occur as a result of myositis. We describe herein the case of a 60‐year‐old man with TRAPS, in whom magnetic resonance imaging of the left thigh demonstrated edematous changes in the muscle compartments and surrounding soft tissues. A full‐thickness wedge biopsy was performed, and hematoxylin and eosin staining and immunohistochemistry analysis of the specimen demonstrated normal myofibrils but a severely destructive monocytic fasciitis. These results suggest that the myalgia experienced by individuals with TRAPS is due to a monocytic fasciitis and not to myositis.
Statistical presentation and analysis of ordered categorical outcome data in rheumatology journals
Authors: LaValley Michael P. , Felson David T. 
Published: October 2002

AbstractObjectiveTo assess the appropriateness of presentation of summary measures and analysis of ordered categorical (ordinal) data in three rheumatology journals in 1999, and to consider differences between basic and clinical science articles.MethodsSix hundred forty‐four full‐length articles from the 1999 editions of 3 rheumatology journals were evaluated for inclusion of an ordinal outcome. Articles were classified as basic or clinical science, and the appropriateness of presentation and analysis of the ordinal outcome were assessed. Chi‐square tests were used to evaluate difference in percentages.ResultsOrdinal outcomes were identified in 175 (27.2%) of 644 articles. Only 69 (39.4%) had appropriate data presentation, and 111 (63.4%) had appropriate data analysis. Appropriate presentation was seen less commonly in the basic science rather than the clinical science articles, but differences in the occurrence of appropriate analysis were not seen.ConclusionOrdinal data are common in rheumatology articles, but presentation usually does not conform to recommended guidelines.
Factors governing 310‐helix vs α‐helix formation in peptides: Percentage of Cα‐tetrasubstituted α‐amino acid residues and sequence dependence
Authors: Crisma Marco , Bisson William , Formaggio Fernando , Broxterman Quirinus B. , Toniolo Claudio 
Published: October 2002

AbstractAs an additional step toward the dissection of the factors responsible for the onset of 310‐helix vs α‐helix in peptides, in this paper we describe the results of a three‐dimensional (3D) structural analysis by x‐ray diffraction of the Nα‐acylated heptapeptide alkylamide mBrBz–L‐Iva–L‐(αMe)Val–L‐Abu–L‐(αMe)Val–L‐(αMe)Phe–L‐(αMe)Val–L‐Iva–NHMe characterized by a single (L‐Abu3) Cα‐trisubstituted and six Cα‐tetrasubstituted α‐amino acids. We find that in the crystal state this peptide is folded in a mixed helical structure with short elements of 310‐helix at either terminus and a central region of α‐helix. This finding, taken together with the published NMR and x‐ray diffraction data on the all Cα‐methylated parent sequence and its L‐Val2 analog (also the latter heptapeptide has a single Cα‐trisubstituted α‐amino acid) strongly supports the view that one Cα‐trisubstituted α‐amino acid inserted near the N‐terminus of an Nα‐acylated heptapeptide alkylamide sequence may be enough to switch a regular 310‐helix into an essentially α‐helical conformation. As a corollary of this work, the x‐ray diffraction structure of the Nα‐protected, C‐terminal tetrapeptide alkylamide Z–L‐(αMe)Val–L‐(αMe)Phe–L‐(αMe)Val–L‐Iva–NHMe, also reported here, is clearly indicative of the preference of this fully Cα‐methylated, short peptide for the 310‐helix. As the same terminally blocked sequence is mixed 310/α‐helical in the L‐Abu3 heptapeptide amide but regular 310‐helical in the tetrapeptide amide and in the parent heptapeptide amide, these results point to an evident plasticity even of a fully Cα‐methylated short peptide. © 2002 Wiley Periodicals, Inc. Biopolymers 64: 236–245, 2002
Antibody production by a hybridoma cell line at high cell density is limited by two independent mechanisms
Authors: Gramer Michael J. , Britton Tracey L. 
Published: October 2002

AbstractOur previous attempt to model the stationary phase of production‐scale hollow‐fiber bioreactors using a scaled‐down micro hollow‐fiber bioreactor resulted in a predicted antibody production rate that was three‐ to fourfold lower than the actual value (Gramer and Poeschl, 2000). Medium limitations were suspected as the reason for the discrepancy. In this study, various increases in medium feed rate were implemented in the micro bioreactor by increasing the diameter of the silicone tubing that houses the hollow fibers. Because larger diameter tubing may induce oxygen limitations, we also explored the effect of medium recirculation to enhance oxygenation. Antibody production in the micro bioreactor increased both as a result of increased medium supply and due to medium recirculation. However, these parameters increased antibody production through two independent mechanisms. The increased medium supply resulted in a higher cell‐specific antibody production rate, but not a higher viable cell density. Medium circulation resulted in the support of a higher viable cell density, but had little effect on the cell‐specific secretion rate. The two mechanisms of enhanced antibody production were additive, demonstrating that simultaneous parameters can limit antibody production by this cell line in a hollow‐fiber system. When the medium feed and circulation rates were increased to a volumetrically proportional scale, scale‐up predictions from the micro bioreactor matched the actual data from the production‐scale system to within 15%. These data demonstrate the usefulness of the micro bioreactor for characterizing cell growth and limiting mechanisms at high cell densities. © 2002 Wiley Periodicals, Inc. Biotechnol Bioeng 79: 277–283, 2002.
Mass transfer effects on the reaction rate for heterogeneously distributed immobilized yeast cells
Authors: Gutenwik Jan , Nilsson Bernt , Axelsson Anders 
Published: October 2002

AbstractHere we examine the efficiency of different immobilized cell gradients applied to immobilized Saccharomyces cerevisiae fermenting glucose to ethanol. We developed a simulation model to fully study the competing effects of mass transfer hindrance and kinetics. It is based on a diffusion‐reaction model and can be used to analyze the different cell concentration profiles inside an immobilized gel bead, in terms of effectiveness factors, productivity, and mass flux. The internal diffusion coefficient, which varies with the local cell concentration, as well as the external mass transfer, is taken into account when describing the efficiency. Although the diffusion hindrance is greater at higher cell concentrations, high cell concentration is still advantageous in the present case because the increase in reaction rate outweighs the diffusion hindrance. Thus, high cell concentrations contribute to increased productivity. The influence of the cell concentration gradient on the efficiency of the beads is negligible. Within the range of cell profiles studied it has been established that the location of the cells within the bead is of lesser importance. However, a steep cell gradient increases the importance of the external mass transfer. © 2002 Wiley Periodicals, Inc. Biotechnol Bioeng 79: 664–673, 2002.
Analysis of growth rate effects on productivity of recombinant Escherichia coli populations using molecular mechanism models
Authors: Lee Sun Bok , Bailey James E. 
Published: October 2002

AbstractThe influence of growth rate on Escherichia coli plasmid content and expression of a cloned‐gene product has been described by a mathematical model based upon the molecular mechanism of λdv plasmid replication and known relationships between growth rate and transcription and translation activities of the host cell. The model simulates correctly decreases in plasmid content with increasing growth rate as observed experimentally for pBR322, NR1, R1, and Col E1 plasmids. A maximum with respect to growth rate in intracellular product accumulation is indicated by the model, as is a transient overshoot in product concentration following a shift from smaller to larger growth rate. Available data, although very limited, show the same trends. These results, obtained without parameter or kinetic form adjustments or manipulation, clearly illustrate the advantages of kinetic descriptions of recombinant systems based upon the pertinent molecular mechanisms. © 2002 Wiley Periodicals, Inc. Biotechnol Bioeng 79: 550–557, 2002.
End‐of‐life care in nursing homes: the interface of policy, research, and practice
Authors: Blevins Dean , Deason‐Howell Lucinda M. 
Published: October 2002

AbstractMuch attention has begun to focus on the quality of care for persons near the end of life. Palliative care, especially through hospice, has generated much discussion as possibly the most holistic care available. Consideration of how chronically ill older adults receive such care as a result of public policy can benefit from adopting a multidimensional perspective. This paper adopts Bronfenbrenner's ecological model to understand current end‐of‐life care for nursing home residents, followed by consideration of how each of these dimensions or levels of influence can be used to foster both research agendas and policy reforms to improve end‐of‐life care of nursing home residents. Specifically, the benefits of considering the influence of such policy initiatives as the Medicare hospice benefit and the Patient Self‐Determination Act (PSDA) on end‐of‐life care in nursing homes and the means through which policy can be informed by clinical research is emphasized. Copyright © 2002 John Wiley & Sons, Ltd.
Professional perpetrators: sex offenders who use their employment to target and sexually abuse the children with whom they work
Authors: Sullivan Joe , Beech Anthony 
Published: October 2002

AbstractProfessionals who use their work as a cover for targeting and sexually abusing children have become the focus of public, media and legislative concerns in recent years. In the past 15 years, scandal after scandal has led to review investigations and public inquiries. These in turn have led to legislative changes to help improve childcare practices and prevent perpetrators from gaining access to children through institutions and organizations. This paper explores the literature and research studies which examine institutional abuse and professional perpetrators. Copyright © 2002 John Wiley & Sons, Ltd.
Creation of an intra‐atrial communication with a new Amplatzer shunt prosthesis: Preliminary results in a swine model
Authors: Kong Huafu , Gu Xiaoping , Titus Jack L. , Kim Tae‐Hoon , Urness Myra , Han Young‐Min , Hessliein Peter , Bass John , Chun Meelee , Hunter David W. 
Published: October 2002

AbstractA nitinol shunt device was applied in six minipigs to create a precise intra‐atrial shunt. This self‐expanding shunt device consists of two retention disks of 2–8 mm, a 4 mm connecting waist with a 10 mm eccentric hole. It requires a 7 Fr introducer sheath. The device is attached to the delivery cable with a microscrew. Placement technique is identical to that of Amplatzer septal occluder. Balloon dilation was performed immediately and 1 month after placement. One animal died from general anesthesia before device placement. Left atrial angiography showed a patent intra‐atrial shunt in 5/5 pigs immediately and 4/4 in 1‐ to 3‐month follow up. Postmortem examination demonstrated patent shunts partially or completely neoendothelialized. The shunt device was found to be an effective and safe way to create a permanent atrial communication. Cathet Cardiovasc Intervent 2002;56:267–271. © 2002 Wiley‐Liss, Inc.
Percutaneous management of access site complications
Authors: Samal Aditya K. , White Christopher J. 
Published: October 2002

AbstractPercutaneous cardiac catheterization and endovascular procedures are associated with complications at the vascular access site. While surgery has been the traditional treatment for vascular access complications, the current state of the art permits percutaneous management of many access site complications. Surgical repair may be required only when percutaneous methods fail, are not available, or are unsuitable. Cathet Cardiovasc Intervent 2002;57:12–23. © 2002 Wiley‐Liss, Inc.
A chemometric study of amino acid transport through liquid membranes using UV‐vis spectroscopy
Authors: Antunes Alexandre M. , Ferreira Márcia M. C. , Volpe Pedro L. O. 
Published: October 2002

AbstractThe extraction of amino acids at 298 K through hydrophobic liquid membranes is studied using the bulk liquid membrane (BLM) method. The transport of different mixtures of phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp) in a buffer solution (pH 1.5) was monitored with a diode array spectrometer by recording their UV‐vis spectra at the receiving phase in small time intervals for 30 min. The apparatus used consisted of a Schulmann cell with the buffer solution as the source phase, reverse micelles of Aerosol‐OT (AOT) in chloroform as the liquid membrane, and a buffer solution at pH 9.0 as the receiving phase. The ordinary least squares (OLS) method was applied separately to each mixture, using the experimental spectra of pure compounds. The transport rates, which are given by the slope of the kinetic curves, were found to be very small, of the order of 10−5, 10−6 and 10−7 mol l−1 min−1 for Phe, Trp and Try respectively. The trilinear decomposition (TLD) method was used to estimate the kinetic profiles for each compound in the ternary mixtures and also their transport rates. They are in fair agreement with those obtained by OLS. Tyr basically does not cross the membrane, so two new experiments were carried out using binary mixtures of Phe and Trp. Their transport rates are of the same order of magnitude as those obtained for the ternary mixtures, and in this case the agreement between TLD and OLS results is excellent. Copyright © 2002 John Wiley & Sons, Ltd.
Survey of factors determining the circularly polarised luminescence of macrocyclic lanthanide complexes in solution
Authors: Bruce James I. , Parker David , Lopinski Stefan , Peacock Robert D. 
Published: October 2002

AbstractThe development of emissive lanthanide complexes as structural or reactive probes to signal changes in their local chiral or ionic environment has been inhibited by the lack of understanding of correlating structural and electronic spectral information. The definition of relatively rigid enantiopure macrocyclic lanthanide complexes, whose inter‐ and intramolecular exchange dynamics have been defined, offers scope for remedying this situation. Chiral axially symmetric lanthanide complexes in solution give rise to large emission dissymmetry values (gem) in CPL spectra. The sign and magnitude of gem are determined by the degree of twist about the principal axis, which is predicted to be a maximum at ±22.5°, and by the site symmetry and local ligand field. In particular, the polarisability of the ligand donor atoms, especially for any axial donor, is very important. Examples of each case are discussed for structurally related cationic Eu(III) complexes. Chirality 14:562–567, 2002. © 2002 Wiley‐Liss, Inc.
High‐grade gliomas in patients with prior systemic malignancies
Authors: Maluf Fernando C. , DeAngelis Lisa M. , Raizer Jeffrey J. , Abrey Lauren E. 
Published: October 2002

AbstractBACKGROUNDThe current study was conducted to characterize the impact of a prior malignancy on the diagnosis, treatment, and outcome of high‐grade glioma.METHODSA retrospective study of 21 patients with a histologic diagnosis of glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), or anaplastic oligodendroglioma (AO) after a prior diagnosis of solid tumor or hematologic malignancy was conducted. Glioma histology (GBM vs. AA/AO), patient age (≤ 60 years vs. > 60 years), and extent of resection (biopsy vs. subtotal vs. complete) were evaluated for their prognostic influence.RESULTSOf the 21 patients studied, 17 had GBM, 3 had AA, and 1 patient had high‐grade AO. There were 25 systemic carcinomas diagnosed in 21 patients (18 solid tumors including breast carcinoma, prostate carcinoma, and melanoma and 7 hematologic malignancies). The glioma occurred within a previous radiation field in only three patients, two of whom had solid tumors and one of whom had a childhood hematologic malignancy. Surgical resection was the initial treatment for the brain tumor in 17 patients, and the majority of patients received radiation therapy and adjuvant chemotherapy. Four patients who initially were misdiagnosed as having brain metastases received whole brain radiation therapy as their initial treatment, thereby compromising optimal care. The overall median survival for all the patients in the current study was 14 months (range, 1–44 months) from the time of brain tumor diagnosis. The extent of resection was found to be the only prognostic variable that was associated with survival (P = 0.03).CONCLUSIONSSecondary glioma may occur in patients as a consequence of therapy for a prior malignancy, but most often represents a sporadic event. The outcome and recommended treatment are identical to those for patients with primary gliomas. Accurate diagnosis is essential; neuroimaging often is suggestive of a primary brain tumor and should initiate surgical intervention so that histopathology can be obtained early and appropriate treatment instituted. Cancer 2002;94:3219–24. © 2002 American Cancer Society.DOI 10.1002/cncr.10595
The bleeding risk index
Authors: Elting Linda S. , Martin Charles G. , Kurtin Danna J. , Cantor Scott B. , Rubenstein Edward B. , Rodriguez Saul , Kanesan Krishnakumari , Vadhan‐Raj Saroj , Benjamin Robert S. 
Published: October 2002

AbstractBACKGROUNDThe correlation between platelet count and bleeding has been well described, although no formal methods for applying this information to clinical decisions are available. The authors developed a clinical prediction rule to guide the prophylactic use of platelet transfusions among patients with lymphoma or solid tumors.METHODSThe Bleeding Risk Index (BRI) was developed from logistic regression analysis of a randomly selected 750‐chemotherapy cycle derivation set using data from Day 1 of cycles. The sensitivity and specificity of a BRI‐based prophylaxis strategy were compared in a 512‐cycle validation set with two strategies based on initiation of prophylaxis when platelet counts fell below thresholds of 20,000 per μL or 10,000 per μL.RESULTSFactors that were predictive of bleeding included any prior episode of bleeding (odds ratio [OR], 5.6; 95% confidence interval [95% CI], 2.2–14.0), treatment with a drug affecting platelet function (OR, 5.1; 95% CI, 2.0–12.6), bone marrow metastases (OR, 4.3; 95% CI, 1.7–10.8), a baseline platelet count < 75,000 per μL (OR, 3.5; 95% CI, 1.4–8.9), genitourinary or gynecologic malignancy (OR, 3.3; 95% CI, 1.3–8.2), a Zubrod performance status score > 2 (OR, 3.4; 95% CI, 1.4–8.5), and treatment with agents that were highly toxic to the bone marrow (OR, 2.2; 95% CI, 1.0–5.4). Compared with 20,000 and 10,000 platelet threshold strategies, the BRI‐based strategy provided the best trade‐off between sensitivity for major bleeding episodes (80%) and specificity for any bleeding (84%).CONCLUSIONSPatients with lymphoma or solid tumors who are at high risk of bleeding can be identified reliably on Day 1 of a chemotherapy cycle. An individualized, BRI‐based approach to bleeding prophylaxis provides a highly sensitive and specific alternative to traditional, nonindividualized platelet threshold strategies. Cancer 2002;94:3252–62. © 2002 American Cancer Society.DOI 10.1002/cncr.10603
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine
Authors: Bellmunt Joaquim , Albanell Joan , Paz‐Ares Luis , Climent Miguel A. , González‐Larriba Jose L. , Carles Joan , de la Cruz Juan J. , Guillem Vicente , Díaz‐Rubio Eduardo , Cortés‐Funes Hernan , Baselga José 
Published: October 2002

AbstractBACKGROUNDNew chemotherapeutic agents, including paclitaxel and gemcitabine, are active in advanced bladder carcinoma, and combination regimens with these agents have shown promising results. Unlike conventional chemotherapy regimens, such as methotrexate, vinblastine, doxorubicin, and cisplatin, there are no data available on key predictive factors for response and survival with these novel agents. Since this information is needed for selection of patients for these new combinations and for stratification purposes in ongoing randomized trials, the authors aimed to study the predictive factors for response and survival to the current regimen containing cisplatin, paclitaxel, and gemcitabine.METHODSThe authors studied 56 patients with advanced urothelial tumors treated on a Phase I/II trial of paclitaxel, cisplatin, and gemcitabine (TCG) to identify pretreatment characteristics that were prognostic for survival using this novel combination. The pretreatment characteristics analyzed were age, gender, Eastern Cooperative Oncology Group performance status, histopathology (pure transitional versus other), visceral (liver, lung, or bone) metastasis, number of sites of disease, lactate dehydrogenase, and hemoglobin.RESULTSThe factors that were associated with a worse survival in univariate analysis were performance status > 0, presence of visceral metastasis, and more than one site of malignant disease. In a multivariate model, performance status (P = 0.044) and visceral disease (P = 0.008) showed independent statistical significance for decreased survival. Patients were then grouped based on these two independent prognostic factors. Median survival times in the groups of patients with zero, one, or two of these risk factors were 32.8 months, 17 months, and 9.6 months, respectively (P = 0.0005).CONCLUSIONSA pretreatment performance status > 0 and the presence of visceral metastasis have a profound impact on survival when using the TCG regimen. These two variables will be used to stratify patients in the upcoming Phase III randomized trial comparing this TGC regimen with a gemcitabine/cisplatin regimen in advanced urothelial tumors. Cancer 2002;95:751–7. © 2002 American Cancer Society.DOI 10.1002/cncr.10762